Attorney Docket No.: ALANEX.006A

AG0035-01 (PC19034A)

REMARKS

+8586788233

Claims 11 and 13-25 are pending. Claims 1-10 and 12 have been canceled without prejudice. Applicants reserve the right to pursue the subject matter of these claims in divisional applications.

Pursuant to applicants' telephone conversation with Examiner Tsang (SPE of Group Art Unit 1625), claim 11 has been amended to delete the word "pharmaceutical". Claim 12 has been deleted in the interests of expediting prosecution. Applicants thank Examiner Tsang for her assistance and believe the claims are now in allowable form. Applicants request that the Examiner allow claims 11 and 13-25 to pass to issuance.

Applicants' undersigned attorney may be reached by telephone at (858) 526-4652. All correspondence should continue to be directed to our address given below. The Commissioner is hereby authorized to charge all fees due including, but not limited to, the fee required under 37 C.F.R. § 1.17(a)(1), or credit any overpayment, to Deposit Account Number 500329.

Respectfully submitted.

July 30, 2004

Wendy L. Hsù Agent For Applicants Registration No. 42,794

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 526-4652

Fax: (858) 678-8233